scispace - formally typeset
F

Feiko O. ter Kuile

Researcher at Liverpool School of Tropical Medicine

Publications -  245
Citations -  14511

Feiko O. ter Kuile is an academic researcher from Liverpool School of Tropical Medicine. The author has contributed to research in topics: Malaria & Population. The author has an hindex of 59, co-authored 218 publications receiving 12969 citations. Previous affiliations of Feiko O. ter Kuile include Malawi-Liverpool-Wellcome Trust Clinical Research Programme & University of Ouagadougou.

Papers
More filters
Journal ArticleDOI

A model of parity-dependent immunity to placental malaria

TL;DR: It is suggested that preventative strategies implementable before or early in pregnancy, such as insecticide-treated net usage in women of child-bearing age or any future vaccine, could substantially reduce the number of women who experience placental infection.
Journal ArticleDOI

Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries.

TL;DR: There is an urgent need to develop targeted pharmacovigilance systems to assess the safety of antimalarials in early pregnancy, according to Feiko ter Kuile and colleagues.
Journal ArticleDOI

The household-level economics of using permethrin-treated bed nets to prevent malaria in children less than five years of age.

TL;DR: Both seasonal effects and number of children per household had larger impacts than ITNs on health care expenditures and time lost from household activities, and the widespread adoption of the ITNs will therefore probably require a subsidy.
Journal ArticleDOI

Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine

TL;DR: Genotyping of P. vivax showed that activation of related (homologous) hypnozoites was the most frequent cause of recurrence, and the high proportion of the impaired CYP2D6 activity among patients with recurrent infections suggests that slow primaquine metabolism might influence related relapse rates in Brazil among patients receivingPrimaquine for radical cure, although confirmatory studies are needed.